Abstract: The present disclosure relates generally to treatment of central nervous system disorders associated with phosphodiesterase 10A (PDE10A) such as schizophrenia, bipolar disease, and Alzheimer's disease, as therapeutics for neurological and psychiatric disorders. This disclosure provides controlled-release formulations of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine (Compound A) and their use in the treatment of schizophrenia and other psychiatric disorders that improves the tolerability profile.

Abstract: Provided herein are methods of treating cancer, an infectious disease, or an infection, which comprise administering to a human patient in need thereof: (a) a TIGIT antagonist; (b) a PD-1 antagonist; and a VEGF antagonist. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer, an infectious disease, or an infection.

Abstract: Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, wherein X1, X2, X3, X4, R1-R4, R5a, R5b, R6a, R6b, R7a, R7b, R8a, R8b, R9-R7 and the subscripts v and w are as herein described can trap IL-1? and are expected to have utility as therapeutic agents, for example, for treating cardiovascular disease. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cardiovascular disease and inflammatory disorders and for preparing pharmaceuticals for this purpose.

Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

Abstract: A microwave vacuum dryer includes a loading chamber and a first vacuum pump in communication with the loading chamber, a first door separating the loading chamber from an external environment, a drying chamber adjacent the loading chamber, a second vacuum pump in communication with the drying chamber, and a condenser in communication with the drying chamber, a second door separating the loading chamber and the drying chamber, an unloading chamber adjacent the drying chamber and a third vacuum pump in communication with the unloading chamber, a third door separating the drying chamber from the unloading chamber, a fourth door separating the unloading chamber from the external environment, and a microwave chamber having a plurality of magnetrons, the microwave chamber positioned on a different plane from the loading and unloading chambers and adjacent the drying chamber.

Abstract: The disclosure provides a novel process and synthetic intermediates for making belzutifan, a HIF-2? inhibitor, useful for the treatment of certain VHL-related indications and cancer.

Abstract: The invention relates generally to the use of chitosan and chitosan derivatives as an adjuvant in a vaccine composition. More specifically, the invention relates to pharmaceutical compositions and formulations that include a low viscosity chitosan or a trimethyl chitosan.

Abstract: Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

Abstract: The present disclosure is directed to compounds that are blockers of NaV1.7 which have the structure of Formula I: or a pharmaceutically acceptable salt thereof.

Abstract: The invention is directed to compounds of Formula I (I) or their pharmaceutically acceptable salts, which may be suitable for imaging alpha-synuclein pathology and hence are useful in binding and imaging alpha-synuclein aggregates in patients with Parkinson's Disease. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study alpha-synuclein in brain in vivo to allow diagnosis of Parkinson's Disease and other neurodegenerative diseases Specific characterized by alpha-synuclein pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Parkinson's Disease and other neurodegenerative diseases characterized by alpha-synuclein pathology.

Abstract: Disclosed herein are polypeptides and polypeptide complexes that are capable of binding tumor cell antigens and effector cell antigens. In some embodiments, the polypeptides and polypeptide complexes bind the tumor cell antigens and the effector cell antigens in a tumor microenvironment.

Abstract: The disclosure describes methods for measuring the potency of anti-Respiratory Syncytial Virus (RSV) antibody against respiratory syncytial virus in a cell culture system using an RSV reporter virus. The disclosure also describes respiratory syncytial viruses that carry a reporter gene, and expression vectors for producing an infectious recombinant respiratory syncytial virus (RSV) that carry a reporter gene.

Abstract: The present disclosure provides, among other things, a lipid nanoparticle adjuvant composition. The present disclosure provides pharmaceutical compositions that include a stable lipid nanoparticle adjuvant and human papillomavirus (HPV) virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.

Abstract: The present invention relates to stable formulations comprising antibodies or antigen-binding fragments thereof that bind to respiratory syncytial virus (RSV). Also provided are methods of preventing and/or treating RSV-related diseases with the formulations of the invention.

Abstract: A proximal subassembly for an injection device includes a thumb press, a base housed within the thumb press, and an internal screw at least partially disposed within the base, the internal screw being configured and arranged to rotate when the thumb press is linearly actuated.

Abstract: The present invention is directed to urea compounds of formula(s) which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.

Abstract: The present invention provides a compound of Formula I wherein R1, R2, R3, R4, R5, R6, R7, and subscripts X and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.

Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.

Abstract: Disclosed are cyclic peptides, their salts, pharmaceutical compositions comprising them, diagnostic and therapeutic uses and processes for making such compounds, which bind to granzyme B and may be suitable for imaging granzyme B. Further provided are compounds useful as a radiotracer for positron emission tomography (PET) and/or single photon emission tomography (SPECT) imaging. The use of the compounds as imaging agents of granzyme B is further disclosed.